Ahmedabad: Zydus Lifesciences Limited (Zydus), an innovation-led life-sciences company with subsidiaries/affiliates in India and across the globe, has entered into a Licensing and Supply Agreement with global pharma major, Lupin Limited (Lupin) to expand access to innovative Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India. This partnership brings together Zydus’ strong product development capabilities and Lupin’s extensive reach in the Indian market, with the shared objective of bringing advanced therapies for metabolic disorders.
Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus’ innovative Semaglutide Injection in the Indian market under the brand names Semanext® and Lupin’s Livarise®. Zydus will market the product under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM. Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.
Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients’ needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India.”
Nilesh Gupta, Managing Director, Lupin, said, ” Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India.”
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy, when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes
It is also indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
